Trusted Resources: News & Meetings
Latest announcements and gatherings
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation Says
The Cure Sanfilippo Foundation is encouraging the U.S. Food & Drug Administration (FDA) to consider Sanfilippo syndrome as a candidate for the agency’s accelerated approval pathway. According to a recent foundation-led study, families of Sanfilippo children are willing to accept modest treatment benefits even if they come with risks.
“Doing nothing is the biggest risk in Sanfilippo!” Glenn O’Neill, foundation president and father to a Sanfilippo child, said in a press release. His statement came at the end of a presentation Oct. 20 at the 13th Annual Rare Disease Scientific Workshop.
The FDA’s Accelerated Approval Program allows for earlier approval of therapies that treat serious conditions and fill an unmet medical need. Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), is a rare genetic disorder characterized by the mutations in genes that encode enzymes that break down the complex sugar molecule known as heparan sulfate.
BookmarkRelated Content
-
Stem Cell Transplant for Bridgnorth Boy With Rare ConditionTwenty-two-month-old Gunner, from Bridgn...
-
Fetal Therapies and Trials for Lysosomal Storage Diseases: A Survey of Attitudes of Parents and PatientsLysosomal storage diseases (LSDs) are in...
-
Genome Editing in Mucopolysaccharidoses and MucolipidosesMucopolysaccharidoses (MPS) and mucolipi...
-
Gene Therapy for Sanfilippo: Where We Are NowGene therapy is a promising approach for...
-
Cure Sanfilippo Foundation – InstagramCure Sanfilippo Foundation is a non prof...
-
Impaired Neural Differentiation of MPS IIIA Patient Induced Pluripotent Stem Cell-Derived Neural Progenitor CellsMucopolysaccharidosis type IIIA (MPS III...
-
The Youngest Pair of Siblings With Mucopolysaccharidosis Type IVA to Receive Enzyme Replacement Therapy to Date: A C...Mucopolysaccharidosis type IVA (OMIM 253...
Powered by
